Related Experiment Video

Updated: May 12, 2026

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma

Brian D Crompton1, Anne L Carlton, Aaron R Thorner

  • 1Department of Pediatric Oncology, Dana-Farber Cancer Institute, Children's Hospital Boston, MA 02215, USA.

Cancer Research
|March 29, 2013
PubMed

Insights

Focal adhesion kinase (FAK) is a promising target for treating pediatric Ewing sarcoma. Inhibiting FAK significantly reduced tumor growth and colony formation in cell lines and in vivo.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Advanced-stage pediatric solid tumors, including Ewing sarcoma, have limited treatment options.
  • Tyrosine kinase inhibitors represent a therapeutic strategy, but specific targets in pediatric cancers are not well-defined.
  • Focal adhesion kinase (FAK) plays a role in cell adhesion, growth, and survival, making it a potential therapeutic target.

Purpose of the Study:

  • To investigate the role of FAK in Ewing sarcoma.
  • To evaluate the efficacy of FAK inhibition as a therapeutic strategy for Ewing sarcoma.

Main Methods:

  • Profiling activated tyrosine kinases using fluorescent bead-based technology.
  • Assessing FAK phosphorylation in primary Ewing sarcoma samples.
  • Downregulating FAK using short hairpin RNA (shRNA) in Ewing sarcoma cell lines.
  • Treating Ewing sarcoma cell lines and in vivo models with a FAK-selective kinase inhibitor (PF-562271).
  • Analyzing downstream signaling pathways including AKT/mTOR and CAS.

Main Results:

  • FAK was found to be highly phosphorylated in primary Ewing sarcoma tumors.
  • FAK downregulation and PF-562271 treatment inhibited Ewing sarcoma cell growth and colony formation.
  • PF-562271 treatment induced apoptosis and downregulated AKT/mTOR and CAS activity.
  • Small-molecule FAK inhibition reduced Ewing sarcoma tumor growth in vivo.

Conclusions:

  • FAK is a critical kinase in Ewing sarcoma development and maintenance.
  • Targeting FAK with kinase inhibitors is a viable therapeutic strategy for Ewing sarcoma.
  • FAK inhibitors, currently in clinical trials for adult cancers, may offer a new treatment avenue for pediatric Ewing sarcoma patients.

More Related Videos

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...